Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 14/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947435 | 0.91 | F10 (0.41) | NPY5RKDM4EMEN1TSHRKMT2A | |
| SCHEMBL2949912 | 0.91 | MAPK1 (0.46) | NPY5RPOLBMAPTMEN1TSHR | |
| SCHEMBL2947431 | 0.91 | F10 (0.41) | NPY5RKDM4EMEN1TSHRKMT2A | |
| SCHEMBL2949907 | 0.91 | MAPK1 (0.46) | NPY5RPOLBMAPTMEN1TSHR | |
| SCHEMBL13290909 | 0.90 | POLB (0.54) | NPY5RPOLBMAPTKDM4EMEN1 | |
| SCHEMBL13290611 | 0.89 | KMT2A (0.44) | NPY5RMAPTKDM4EMEN1TSHR | |
| SCHEMBL13290695 | 0.88 | NPY5R (0.39) | NPY5RMAPTKDM4EMEN1KMT2A | |
| SCHEMBL13290693 | 0.86 | MEN1 (0.52) | POLBMAPTKDM4EMEN1TSHR | |
| SCHEMBL2949749 | 0.85 | MEN1 (0.44) | POLBMAPTKDM4EMEN1TSHR | |
| SCHEMBL2949751 | 0.85 | MEN1 (0.44) | POLBMAPTKDM4EMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | NPY5R 805/4885POLB 2463/4885MAPT 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.